How CVS Health’s (CVS) Cost-Saving Overhaul in Medicare and Pharmacy Benefits Has Changed Its Investment Story

• CVS Health recently announced significant adjustments to its Medicare Advantage and pharmacy benefit offerings, including reducing coverage in select markets while expanding specialized plans for dual-eligible and chronically ill members, and introducing a new $200 copay program for Novo Nordisk's Wegovy through its pharmacy benefits manager, Caremark.
• These measures aim to address rising healthcare costs and market pressures by balancing targeted access improvements and overall cost containment for health plans and patients.
• We'll examine how CVS Health's emphasis on cost-saving initiatives for high-demand medications could shift its investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

CVS Health Investment Narrative Recap

To be a CVS Health shareholder, you need to believe in the long-term value of its integrated healthcare model, including the ability to adapt amid industry shifts, cost pressures, and evolving consumer behavior. The recent reopening of the Pacific Palisades store following wildfire damage demonstrates CVS Health’s operational resilience and commitment to community engagement; however, this event does not materially impact the current key catalyst of Medicare Advantage growth or the primary risk of sustained margin pressure in the Health Care Delivery segment.

Among recent announcements, CVS Health’s move to expand select pharmacy and health services, including in-store clinical offerings and care delivery improvements, stands out. This supports the ongoing catalyst of increasing demand from an aging population while maintaining relevance for short-term growth drivers, though the long-term challenge of front-end retail sales remains. Although CVS has shown strong operational adaptability, investors should also be mindful of the risk that...

Read the full narrative on CVS Health (it's free!)

CVS Health's outlook anticipates $445.1 billion in revenue and $8.3 billion in earnings by 2028. This is based on a projected annual revenue growth rate of 5.0% and represents a $3.8 billion increase in earnings from the current $4.5 billion.

Uncover how CVS Health's forecasts yield a $82.07 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Thirteen members of the Simply Wall St Community estimate CVS Health’s fair value between US$62 and US$276 per share. Margin pressure in health care delivery remains top of mind for many, shaping wide-ranging opinions on the company’s earnings prospects and making it valuable to consider several distinct viewpoints.

Explore 13 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!

Build Your Own CVS Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com